title: Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review.
abstract: BACKGROUND
  Paliperidone (9-hydroxyrisperidone), the major active metabolite of risperidone, has been introduced as a novel atypical antipsychotic agent in many countries. It is available both as an oral extended-release (ER) formulation and as a long-acting injection (paliperidone palmitate, PP), which have been approved for treating schizophrenia in the People's Republic of China since 2009 and 2012, respectively. This systematic review summarizes the efficacy, effectiveness, and safety of paliperidone in the treatment of schizophrenia in the Chinese population.
  
  
  METHODS
  A systematic literature search was conducted on the databases covering international and Chinese core journals, published from January 1, 2008, to May 22, 2015.
  
  
  RESULTS
  A total of 122 publications were retrieved, of which 63 studies were identified for inclusion; most studies were related to paliperidone ER (n=53), nine were related to PP, and one study was related to both agents. Paliperidone ER demonstrated at least comparable efficacy with active comparators, including risperidone, olanzapine, ziprasidone, or aripiprazole, and was found to be superior with respect to the onset of action and improvement in the Personal and Social Performance Scale score. Paliperidone ER appeared to be associated with a lower risk of metabolic syndromes; the most common treatment-emergent adverse events were extrapyramidal symptoms, akathisia, insomnia, and somnolence. Results from interventional and observational studies showed that PP was also an effective and well-tolerated treatment for Chinese patients with schizophrenia. The findings were generally consistent with those observed in non-Chinese populations.
  
  
  CONCLUSIONS
  Both paliperidone ER and PP were effective and well-tolerated agents for the treatment of schizophrenia in the Chinese population according to the data we reviewed. No new safety signals specific for the Chinese population were raised for paliperidone. Further studies may be needed to collect more data on long-term treatment of schizophrenia in the People's Republic of China.
authors.affiliation: Medical Affairs, Xian Janssen Pharmaceutical Co, Ltd, Beijing, People's Republic of China.
authors.forename: LiLi
authors.initials: L
authors.lastname: Zhang
authors.affiliation: National Clinical Research Center for Mental Disorders, Beijing, People's Republic of China; Peking University Sixth Hospital, Institute of Mental Health, Beijing, People's Republic of China; The Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, People's Republic of China.
authors.forename: JiTao
authors.initials: J
authors.lastname: Li
authors.affiliation: National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
authors.forename: YanJie
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: National Clinical Research Center for Mental Disorders, Beijing, People's Republic of China; Peking University Sixth Hospital, Institute of Mental Health, Beijing, People's Republic of China; The Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, People's Republic of China.
authors.forename: Yun'Ai
authors.initials: Y
authors.lastname: Su
authors.affiliation: National Clinical Research Center for Mental Disorders, Beijing, People's Republic of China; Peking University Sixth Hospital, Institute of Mental Health, Beijing, People's Republic of China; The Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, People's Republic of China.
authors.forename: Tianmei
authors.initials: T
authors.lastname: Si
keywords: antipsychotics; effectiveness; efficacy; paliperidone; safety
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8
references.pmid: 21315787
references.citation: Lancet. 2009 Jun 13;373(9680):2041-53
references.pmid: 19524780
references.citation: Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73
references.pmid: 8935801
references.citation: Psychopharmacology (Berl). 2013 Nov;230(1):3-13
references.pmid: 23559220
references.citation: Hum Psychopharmacol. 2012 Nov;27(6):605-14
references.pmid: 24446539
references.citation: Curr Med Res Opin. 2006 Oct;22(10):1879-92
references.pmid: 17022845
references.citation: Int Clin Psychopharmacol. 2015 Jul;30(4):230-6
references.pmid: 25882381
references.citation: BMC Clin Pharmacol. 2012 Jan 06;12:1
references.pmid: 22225965
references.citation: J Clin Pharmacol. 2014 Sep;54(9):1048-57
references.pmid: 24676998
references.citation: Am J Health Syst Pharm. 2012 Nov 1;69(21):1872-9
references.pmid: 23111671
references.citation: Zhonghua Yi Xue Za Zhi. 2010 Aug 3;90(29):2030-5
references.pmid: 21029638
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2014 Aug 4;53:45-53
references.pmid: 24576532
references.citation: Hum Psychopharmacol. 2014 Mar;29(2):203-10
references.pmid: 24590546
references.citation: Psychiatr Q. 2011 Dec;82(4):343-51
references.pmid: 21499787
references.citation: Drug Metab Dispos. 1993 Nov-Dec;21(6):1134-41
references.pmid: 7507814
references.citation: Psychol Med. 2010 Jun;40(6):935-44
references.pmid: 19751542
references.citation: Neuropsychiatr Dis Treat. 2015 Jul 23;11:1817-34
references.pmid: 26229477
references.citation: J Clin Psychiatry. 2013 Oct;74(10):957-65
references.pmid: 24229745
references.citation: Hum Psychopharmacol. 2010 Jul;25(5):404-9
references.pmid: 20589922
references.citation: Adv Med Sci. 2007;52 Suppl 1:108-11
references.pmid: 18229644
references.citation: Neuropsychiatr Dis Treat. 2015 Mar 11;11:657-68
references.pmid: 25792835
references.citation: Curr Med Res Opin. 2010 Feb;26(2):377-87
references.pmid: 20001492
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1022-31
references.pmid: 19481579
references.citation: Neuropsychiatr Dis Treat. 2015 Jan 06;11:87-95
references.pmid: 25657581
references.citation: Schizophr Bull. 2000;26(1):119-36
references.pmid: 10755673
references.citation: Obesity (Silver Spring). 2008 Apr;16(4):749-54
references.pmid: 18239573